{"id":"W2067945145","doi":"10.1016/j.urology.2013.02.077","title":"A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder","year":2013,"lang":"en","type":"article","venue":"Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Mirabegron; Medicine; Overactive bladder; Placebo; Tolerability; Urination; Adverse effect; Randomized controlled trial; Urinary incontinence; Clinical endpoint; Urology; Anesthesia; Internal medicine; Urinary system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002777208,0.002249705,0.005600832,0.000585902,0.0009818082,0.001383476,0.001374637,0.00256056,0.004891682],"category_scores_gemma":[0.002807455,0.001188998,0.002267825,0.0007269831,0.002189024,0.001428594,0.000573119,0.003972147,0.001014373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001038378,"about_ca_system_score_gemma":0.002766735,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00150894,"about_ca_topic_score_gemma":0.0032107,"domain_scores_codex":[0.9990498,0.0004641834,0.00006431663,0.000179203,0.00008072569,0.0001616815],"domain_scores_gemma":[0.998206,0.0004287675,0.0003341417,0.000210272,0.0001501583,0.000670623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9790201,0.01089283,0.0003440731,0.0003608224,0.0005554823,0.00002486788,0.00005845911,0.0001830177,0.002755706,0.00006389606,0.0004184334,0.00532228],"study_design_scores_gemma":[0.9645113,0.03424082,0.0006325331,0.000008663423,0.0001447439,0.0000120089,0.000009049702,0.00009454409,0.0001337668,0.00004319513,0.0001619412,0.000007509596],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775984,0.003946831,0.001975245,0.0009527858,0.0008219921,0.0110808,0.001406599,0.0002314835,0.001985835],"genre_scores_gemma":[0.9687209,0.002962995,0.005221076,0.002980286,0.0007878003,0.01439734,0.00182521,0.00006340787,0.00304099],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005600832,"threshold_uncertainty_score":0.01636434,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01888913307314922,"score_gpt":0.3087143719147672,"score_spread":0.289825238841618,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}